208 related articles for article (PubMed ID: 38041022)
1. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.
Zhang R; Zhao H; Wang P; Guo Z; Liu C; Qu Z
BMC Cancer; 2023 Dec; 23(1):1181. PubMed ID: 38041022
[TBL] [Abstract][Full Text] [Related]
2. The combination of circulating IgM and geriatric nutritional risk index predicts the prognostic of hepatocellular carcinoma patients who underwent immune checkpoint inhibitors.
Liu C; Zhao H; Wang P; Guo Z; Qu Z
Int Immunopharmacol; 2023 Oct; 123():110704. PubMed ID: 37506504
[TBL] [Abstract][Full Text] [Related]
3. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors.
Liu C; Zhao H; Zhang R; Guo Z; Wang P; Qu Z
Oncol Lett; 2023 Oct; 26(4):437. PubMed ID: 37664652
[TBL] [Abstract][Full Text] [Related]
5. Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma.
Du J; Huang Z; Zhang E
Front Immunol; 2024; 15():1329634. PubMed ID: 38304429
[TBL] [Abstract][Full Text] [Related]
6. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.
Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J
Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080
[TBL] [Abstract][Full Text] [Related]
7. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
8. Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors.
Xiong B; Fu B; Wu Y; Gao F; Hou C
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11607-11617. PubMed ID: 37400572
[TBL] [Abstract][Full Text] [Related]
9. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.
Tian BW; Yan LJ; Ding ZN; Liu H; Han CL; Meng GX; Xue JS; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
Int Immunopharmacol; 2023 Jan; 114():109519. PubMed ID: 36459922
[TBL] [Abstract][Full Text] [Related]
10. Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma.
Li X; Sun W; Ding X; Li W; Chen J
Front Immunol; 2022; 13():1060051. PubMed ID: 36532029
[TBL] [Abstract][Full Text] [Related]
11. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
Wang R; Lin N; Mao B; Wu Q
J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol and C-reactive protein prognostic score predicted prognosis of immune checkpoint inhibitors based interventional therapies for intermediate-to-advanced hepatocellular carcinoma patients.
Zeng H; Zhang D; Yang Z; Hu Z; Yang Z; Fu Y; Hou J; Ngai S; Wang J; Chen J; Hu D; Zhou Z; Chen M; Zhang Y; Pan Y
Int Immunopharmacol; 2023 Feb; 115():109651. PubMed ID: 36638663
[TBL] [Abstract][Full Text] [Related]
15. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
[TBL] [Abstract][Full Text] [Related]
16. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.
Sun T; Guo Y; Sun B; Chen L; Ren Y; Zhu L; Zhang L; Liu Y; Zheng C
Eur J Med Res; 2023 Jul; 28(1):225. PubMed ID: 37408056
[TBL] [Abstract][Full Text] [Related]
17. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.
Tian BW; Yan LJ; Ding ZN; Liu H; Meng GX; Xue JS; Han CL; Dong ZR; Hong JG; Chen ZQ; Wang DX; Li T
Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):73-83. PubMed ID: 36476076
[TBL] [Abstract][Full Text] [Related]
18. C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients.
Zhang Y; Lu L; He Z; Xu Z; Xiang Z; Nie RC; Lin W; Chen W; Zhou J; Yin Y; Xie J; Zhang Y; Zheng X; Zhu T; Cai X; Li P; Chao X; Cai MY
Front Immunol; 2022; 13():808101. PubMed ID: 35185894
[TBL] [Abstract][Full Text] [Related]
19. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
Front Immunol; 2021; 12():676922. PubMed ID: 34335575
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of inflammation-immunity-nutrition score in patients with hepatocellular carcinoma treated with anti-PD-1 therapy.
Zhang Z; Liang Y; Zhong D; Dai Z; Shang J; Lai C; Zou H; Yao Y; Feng T; Huang X
J Clin Lab Anal; 2022 May; 36(5):e24336. PubMed ID: 35312116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
